Exact Metrology Scans Vertebrae Plate

Exact Metrology: A Division of In-Place Machining Company and a comprehensive 3D metrology service provider and hardware sales company, scanned a titanium cervical spine locking plate.

The scan was completed by Brendon Belongia, an Applications Engineer at the Brookfield, Wisconsin office using the ZEISS METROTOM 6 scout.

The METROTOM 6 scout digitizes complex parts including the internal geometries at the finest level of detail. Users obtain a complete 3D image for GD&T analysis or nominal-actual comparisons. High-resolution images can be captured for precise measuring tasks or detailed inspections of internal structures. Be it shrinkage holes, pores, cracks, sink marks, or warpage, all defects or deviations can be detected non-destructively.

Furthermore, the combination of a 3k detector and 225 kV X-ray enables ZEISS METROTOM 6 scout to provide high contrast, high-resolution measurement results and exceptional sharpness of detail. As a result, even the smallest defects in the part become visible and can be analyzed to the last detail. A 5-axis kinematics with an integrated centering table helps clients optimally position the part in the measuring volume and the control of the device and the metrological evaluation of the data are combined in a single software package, making additional software or intermediate steps redundant.

With this CT scan, the company demonstrates its ability to scan even the smallest part, such as 4 mm. This vertebrae plate was measured within a 5-micron resolution and used a deviation color map with the GOM Volume Inspect software. The color representation of a point cloud or mesh data set is compared to its intended, nominal CAD model.  This spectrum of colors can tell users how far a value deviates compared to the CAD surfaces. Thus, a weak spot can be detected and can be fixed before a part is used.

The ability of the ZEISS METROTOM 6 scout to see the tinniest defect or detail is especially crucial for medical devices, especially those that go into the human body.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”